A study by the University of Southern California, published in The Journal of Infectious Diseases, explores the potential of the novel marker HBV RNA in assessing the likelihood of sustained partial cure in patients who discontinue therapy.
Phone · +86 021-50720200 Address · Building 15B, No. 528 Ruiqing Road, East District, Zhangjiang High tech Park, Shanghai Email · hr@rdbio.com（Domestic Affairs） sales@rdbio.com（International Trade）
